Status:
TERMINATED
Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Hypertrophic Cardiomyopathy
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The objective is to determine whether 99Technetium-NC100692 uptake in patients with ACS (MI) can serve as a marker for scar formation as detected by contrast-enhanced MRI during the process of myocard...
Detailed Description
HCM Population: The primary objective is to determine whether fibrosis detected by MRI and 99mTc-NC100692 uptake in patients with HCM are associated. The secondary objective is to determine whether 9...
Eligibility Criteria
Inclusion
- HCM Population:
- Diagnosis of HCM as defined as: Interventricular septal thickness greater than 12 mm on a 2D echocardiogram, or septal: posterior wall thickness as measured on parasternal long axis view of \>1.3 in the absence of secondary causes of cardiac hypertrophy such as aortic stenosis and systemic hypertension.
Exclusion
- Concomitant diseases that can lead to myocardial hypertrophy including valvular heart disease and uncontrolled hypertension. If HCM is proven by either the presence of a family history of HCM or through genotyping, patients with controlled hypertension will not be excluded.
- Documented coronary artery disease including a history of previous myocardial infarction or coronary intervention or revascularization.
- Known diabetic cardiomyopathy.
- ACS Population:
- Inclusion Criteria:
- Diagnosis of ACS, either NSTEMI as determined by positive myocardial markers or STEMI patients who have an onset of symptoms 12 hours or less before presentation and an ST-segment elevation of at least 1 mm in two or more contiguous limb leads or of at least 2 mm in two or more contiguous precordial leads during prehospital 12-lead ECGs. Patients will undergo 99mTc-NC100692 imaging within 1 week of acute myocardial infarction.
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 20 2017
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01230918
Start Date
May 1 2011
End Date
April 20 2017
Last Update
April 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7